What Are the Effects of Lymphedema Treatment
Conditions
Keywords
Breast cancer, Lymphedema, Oxidative stress
Brief summary
It is aimed to determine the changes of complex decongestive therapy applications on oxidative stress parameters and antioxidants in patients with lymphedema after breast cancer treatment.
Detailed description
Lymphedema, which is the most common late complication of patients undergoing cancer treatment, affects the physical, social and psychological lives of the individual and decreases the quality of life as it causes motor dysfunctions, cosmetic deformations and psychological disorders. The addition of radiotherapy to surgical intervention increases the risk of lymphedema by 36%. When free radicals increase in intensity, they cause structural defects in lipids, proteins and nucleic acids, and as a result, they are a cause and risk factor for chronic diseases such as cancer, neurodegenerative diseases and cardiovascular diseases. Cancer cells produce high levels of reactive oxygen species (ROS) due to their fast metabolism and impaired cellular signaling mechanisms. High levels of ROS are generally harmful to cells and the redox state of cancer cells is different from normal cells. Therefore, cancer cells maintain ROS levels at a moderately high tumorigenic level, above the low cytostatic level, but below levels that may be cytotoxic. The oxidative stress state in a cancer cell is different from the oxidative stress state in a normal cell. It is also well known that increased oxidative stress and inflammation are associated with cancer risk. The number of studies investigating the effect of complex decongestive therapy, which is stated to be the most effective treatment method in the treatment of lymphedema, the most common complication after breast cancer treatment, on oxidative stress and antioxidant levels is quite limited. In this study, it was aimed to reveal the changes of complex decongestive therapy applications on oxidative stress parameters and antioxidants in participants with lymphedema after breast cancer treatment.
Interventions
Complex decongestive therapy consists of 4 phases. It will be performed by a lymphedema physiotherapist trained in Complex Decongestive Physiotherapy. Complex decongestive therapy consists of manual lymph drainage, skin care, multilayer bandaging and therapeutic exercises.
Sponsors
Baskent University
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
SINGLE (Subject)
Masking description
1. Study Group-Patient with Lymphedema 2. Control Group-Healthy Group
Intervention model description
1. Working Group (Complex decongestive therapy) 2. Control Group
Eligibility
Sex/Gender
FEMALE
Age
25 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Development of lymphedema after breast cancer treatment * Clinical stage of lymphedema Stage-2 or Stage-3 diagnosis
Exclusion criteria
* Receiving treatment for lymphedema in the last three months * Those diagnosed with severe heart failure and/or arrhythmia * Persistent infection in the affected extremities * Ongoing chemotherapy treatment * Diagnosed with liver disease
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| PON1 | will be assessed before treatment, immediately after treatment and one month after treatment. | Paraoxonase |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| OSİ | will be assessed before treatment, immediately after treatment and one month after treatment. | Oxidative Stress Index |
Other
| Measure | Time frame | Description |
|---|---|---|
| Trigliserit | will be assessed before treatment, immediately after treatment and one month after treatment. | level of Trigliserit |
| LDL | will be assessed before treatment, immediately after treatment and one month after treatment. | Low danditelilipoprotein |
| MDA | will be assessed before treatment, immediately after treatment and one month after treatment. | malonDialdehyde |
| GSH | will be assessed before treatment, immediately after treatment and one month after treatment. | Rduktegulutathion |
| HDL | will be assessed before treatment, immediately after treatment and one month after treatment. | High densitelilipoprotein |
Countries
Turkey (Türkiye)
Outcome results
None listed